Q-omics provides the consensus-scored KLHDC8B profile across patient tissues and cancer cell-line models. KLHDC8B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, KLHDC8B is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, KLHDC8B RNA expression shows 18,339 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, THCA, and ACC as cancer lineages where KLHDC8B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHDC8B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHDC8B survival associations across molecular data types. KLHDC8B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHDC8B RNA expression–survival associations across cancer types. High KLHDC8B expression shows unfavorable associations in LIHC and KICH, but favorable associations in LUAD, KIRC, DLBC and SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for KLHDC8B RNA expression.
This table summarizes KLHDC8B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KLHDC8B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHDC8B shows lower tumor expression in THCA, KICH, HNSC, UCEC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher KLHDC8B RNA expression in normal versus tumor tissue (log2 FC = −1.463, t-test p < 0.001).
This table shows molecular features associated with KLHDC8B in patient tissues and cancer cell lines. In patient samples, KLHDC8B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHDC8B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
